Affiliation: | a Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA b Department of HTS & Molecular Pharmacology, Amgen Inc., 360 Binney Street, Cambridge, MA 02142 and Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA c Department of Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA d Department of Oncology Research, Amgen Inc., 360 Binney Street, Cambridge, MA 02142 and Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA e Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA f Department of Toxicology, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA g Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA h Department of Metabolic Disorders, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA |
Abstract: | The insulin-like growth factor-1 receptor (IGF-1R) plays an important role in the regulation of cell growth and differentiation, and in protection from apoptosis. IGF-1R has been shown to be an appealing target for the treatment of human cancer. Herein, we report the synthesis, structure-activity relationships (SAR), X-ray cocrystal structure and in vivo tumor study results for a series of 2,4-bis-arylamino-1,3-pyrimidines. |